Hot Off the Presses:
Latest in Alzheimer’s & Dementia Research
Our Time Today …

• Landscape of Alzheimer’s and dementia
• Advances in understanding of Alzheimer’s
• Highlights in early detection and diagnosis
• Latest advances from AAIC on clinical trials – medicines and lifestyle
• How to get involved today
OUR VISION: A world without Alzheimer’s disease®.

OUR MISSION: To eliminate Alzheimer's disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health.
We Fund ...

HIGHEST IMPACT NON-PROFIT!

- InCITES
Awareness Continues to Grow

#EndALZ

The First Survivor of Alzheimer's Disease is Out There.

We won't get there without you. Visit alz.org to join the fight.
National Plan to Address Alzheimer’s Disease

“Prevent & Effectively Treat Alzheimer’s by 2025”

4X NIH Budget since 2012 for Alzheimer’s & Related Dementia

Alzheimer’s Association is leading the way!
We Advocate

Alzheimer’s and Related Dementia Research Funding at the NIH

Definitions: Dementia & Alzheimer’s

Dementia
An "umbrella" term used to describe a range of symptoms associated with cognitive impairment.

Alzheimer’s 50%-75%
Vascular 20%-30%
Lewy Bodies 10%-25%
Frontotemporal 10%-15%

Mixed Dementia = >1 Neuropathology - Prevalence Unknown

Tangles
Plaques
β-Amyloid plaques

Tau tangles

Brain cell death

Biology Impacts Behavior
Impact of Alzheimer’s

Total cost of care for those with Alzheimer's, with more than two-thirds paid by Medicare and Medicaid.
2/3 of Americans with Alzheimer's are women.
A Woman’s Reproductive History and Risk for Dementia

- Lower dementia risk associated with:
  - Number of children
  - Months spent pregnant
  - History of miscarriage
  - Age of first menstrual period
  - Age of menopause

Funded $3M+ to 13 projects in 2017 and 2018 to help answer why!
Continuum of Alzheimer’s disease

Cognitively Unimpaired  

Alz dementia

BIOMARKERS

History & Cognition
DETECTING BRAIN CHANGES
Biomarkers Changed the Game

• Alzheimer’s Association advanced development and utilization of biomarkers
• Amyloid and Tau detected in Cerebrospinal Fluid & by PET
• Research use years before symptoms appear
Progress Toward More Effective Treatment By 2025

Medicines

Lifestyle/ Behavior
Progress Toward More Effective Treatment By 2025

Medicines
Current Landscape of Clinical Trials for Alzheimer’s & Dementia

Phase I: 95
Phase II: 166
Phase III: 61

Need for participants

Please note that an agent or device may be associated with more than one active clinical trial.

As of 04/2018
Continuum of Alzheimer’s disease

Cognitively Unimpaired

Alz dementia
Nabilone decreases agitation in people with moderate to severe Alzheimer’s

- Non-cognitive symptoms: agitation, sleep disturbances, apathy, depression
- Nabilone:
  - Synthetic cannabinoid; not marijuana
  - Small study (39 people)
  - Saw benefit on agitation in participants
- Needs replication in a larger study
Moving the needle at an accelerated pace!
BAN2401 Reports Phase 2b Results

• Adaptive study design in people w/early Alzheimer’s
• Targeting beta amyloid
• Second drug trial lowering:
  – Reduced beta-amyloid (PET)
  – Suggests improved cognition
  – Aducanumab (Phase 3)
• Intriguing results; must be studied in larger trial
Possibility of Prevention

ACCELERATED 3 YEARS!
Progress Toward More Effective Treatment By 2025

Lifestyle/ Behavior
SPRINT-MIND Study: First Study to Demonstrate Reduction of New Cases

- 9,000+ ppl; std vs intensive
- Intensive treatment:
  - 19% reduced risk for MCI
  - 15% reduced combined MCI and dementia
- Dramatic reduction of small vessel disease on MRI
- Immediate opportunity with life changing impact potential
Does a recipe that combines lifestyle interventions prevent or delay cognitive decline?

U.S. POINTER will evaluate two lifestyle interventions.
If we **delay** onset by 5 years...

**DELAYED ONSET**
If we develop a treatment by 2025 that delays the onset of Alzheimer’s by just five years, then:

- 5.7 MILLION people expected to develop Alzheimer’s would not in 2050.

*Changing the Trajectory of Alzheimer’s Disease: How a Treatment by 2025 Saves Lives and Dollars*
2018 Charlotte Walk Event Information

When: Saturday, October 13, 2018
Where: BB&T Ballpark – 324 S. Mint Street

When: Registration: 9:00 a.m., Walk: 10:30 a.m.

Register today! Visit alz.org/walk or call 800.272.3900
In Summary …

• Significant advances in our understanding of the disease, tools for early detection and diagnosis, and growing diversity of therapies being investigated

• Alzheimer’s Association is the global leader – funder, convener, advocate – to Alzheimer’s and dementia science

• We ARE making significant advances … There is HOPE in research!!!
thank you!
TOGETHER, WE CAN END ALZHEIMER’S DISEASE.™

ALZHEIMER’S IS RELENTLESS. SO ARE WE.

Alamance Co.............................9/22
Asheville........................................9/15
Charlotte........................................10/13
Gastonia........................................9/08
Guilford Co....................................10/20
Hendersonville..............................9/29
Hickory..........................................10/27
Iredell Co......................................10/06
Moore Co.......................................10/06
Mount Airy......................................9/08
N. Wilkesboro.................................10/13
Randolph Co.................................10/20
Rowan-Cabarrus Co..........................9/15
Winston-Salem...............................10/27

2018

WALK TO END ALZHEIMER’S

Register today! Visit alz.org/walk or call 800.272.3900

alzheimer’s association®